Burning Rock Biotech Reports Q1 2025 Financial Results and Advances in Oncology Research

An announcement from Burning Rock Biotech ( (BNR) ) is now available.

Burning Rock Biotech reported its financial results for the first quarter of 2025, showing a revenue increase of 5.9% compared to the same period in 2024, reaching RMB133.1 million. The company highlighted significant business updates, including advancements in personalized Minimal Residual Disease (MRD) products and studies on esophageal squamous cell carcinoma, non-small cell lung cancer, and gastrointestinal stromal tumor. Despite a decrease in central laboratory business revenue, the in-hospital business and pharma research services showed growth. The company also achieved a reduction in operating expenses by 46.8% due to budget control measures and headcount reductions, resulting in a net loss of RMB13.5 million, a significant improvement from the previous year’s loss.

Spark’s Take on BNR Stock

According to Spark, TipRanks’ AI Analyst, BNR is a Neutral.

Burning Rock Biotech faces significant financial and valuation challenges, with declining revenues and persistent net losses impacting its overall score. Technical analysis provides a mixed outlook, with no clear trend. The company’s negative P/E ratio and lack of dividend yield further diminish its attractiveness.

To see Spark’s full report on BNR stock, click here.

More about Burning Rock Biotech

Burning Rock Biotech Limited, listed on NASDAQ as BNR, is a company dedicated to the application of next generation sequencing (NGS) technology in precision oncology. The company focuses on NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which is in the clinical validation stage.

Average Trading Volume: 33,232

Technical Sentiment Signal: Sell

Current Market Cap: $31.21M

See more insights into BNR stock on TipRanks’ Stock Analysis page.